Circulating tumor nucleic acid detection method using gold island enhanced multiple quantum dot fluorescence strategy

Abstract

The invention discloses a circulating tumor nucleic acid detection method using a gold island enhanced multiple quantum dot fluorescence strategy, and specifically discloses a gold island enhanced multiple quantum dot chip and a preparation method thereof, and a circulating tumor nucleic acid detection method using the gold island enhanced multiple quantum dot fluorescence strategy. According to the circulating tumor nucleic acid detection method using a gold island enhanced multi-quantum dot fluorescence strategy, a KRAS gene single / multi-base mutation detection method in a clinical tumor patient blood sample using the gold island enhanced multi-quantum dot fluorescence strategy is used. The method has the advantages that the signal acquisition sensitivity is high, visualization is realized, and quantitative statistical analysis can be realized; the sample compatibility is good; operation is simple and rapid, and sample amplification is not needed; and the detection process is simple,CTNAs can be detected through a simple sample extraction process, consumed time is short, the amplification step is omitted, and detection is rapid.

Description

technical field [0001] The invention relates to the technical field of nucleic acid detection, in particular to the detection technology of circulating tumor nucleic acid. Background technique [0002] Circulating tumor nucleic acids (CTNAs) are cell-free nucleic acids released by tumor lesions, which have been considered as potential markers for tumor diagnosis and therapy. Studies have shown that the concentration and mutation probability of CTNAs in tumor patients are usually higher than those in healthy people, and the diagnostic strategy relying on CTNAs in blood samples can be used as a method for tumor liquid biopsy, and may become a supplementary or alternative method for tumor tissue biopsy. However, the concentration and mutation probability of CTNAs in plasma or serum samples vary greatly; the low expression level of some CTNAs leads to the need for more than 10ml serum to obtain sufficient target CTNAs substrates during clinical testing. Based on the polymerase ...

AI Technical Summary

Problems solved by technology

However, the concentration and mutation probability of CTNAs in plasma or serum samples vary greatly; the low expression level of some CTNAs leads to the need for more than 10ml serum to obtain sufficient target CTNAs substrates during clinical testing

Based on the polymerase chain reaction (PCR), the sensitivity and specificity of the detection are guaranteed, but the point mutations of CTNAs cannot be effectively detected; DNA sequencing can effectively detect the mutant fragments of CTNAs, but it is expensive, time-consuming, and greatly limited its clinical application

The above factors have caused great obstacles to the detection of CTNAs and subsequent analysis

Images